Citron Research failed to release additional fraud allegations against Valeant Pharmaceuticals International Inc. (Nasdaq: VRX) after promising that more charges would be made public. The stock price leaped $6.70 to close at $100.47.
No new allegations against Valeant Pharmaceuticals
November 02, 2015 at 19:04 PM EST
